

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
14 March 2024 (14.03.2024)



(10) International Publication Number
WO 2024/052514 A1

(51) International Patent Classification:

A61K 31/519 (2006.01) A61P 35/00 (2006.01)
A61K 31/7048 (2006.01) C07K 16/28 (2006.01)
A61K 33/243 (2019.01) A61N 5/10 (2006.01)
A61K 39/395 (2006.01)

(21) International Application Number:

PCT/EP2023/074693

(22) International Filing Date:

08 September 2023 (08.09.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/405,139 09 September 2022 (09.09.2022) US

(71) Applicant: **ASTRAZENECA AB** [SE/SE]; SE-151 85
Södertälje (SE).

(72) Inventor: **JIANG, Haiyi**; Astrazeneca Pharmaceuticals
LP, 1800 Concord Pike, P.O. Box 15437, Wilmington,
Delaware 19850-5437 (US).


(74) Agent: **ASTRAZENECA INTELLECTUAL PROPER-
TY**; Association 813, Eastbrook House, Shaftesbury Road,
CAMBRIDGE Cambridgeshire CB2 8BF (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: COMPOSITIONS AND METHODS FOR TREATING ADVANCED SOLID TUMORS

PFS and OS: SCLC Arms 3 & 4 by Treatment Arm



(57) Abstract: Disclosed are methods for treating solid tumors with an anti-PD-L1 antibody and an anti-CTLA-4 antibody concurrently with chemoradiation therapy (cCRT).

[Continued on next page]

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*